|
Video: What is a Stock Split?
|
|
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company developing a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. Tumor infiltrating lymphocyte therapy is an autologous, polyclonal cell therapy platform technology that was developed by the National Cancer Institute which conducted initial clinical trials of this therapy in diseases such as metastatic melanoma and cervical cancer. Co.'s primary product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer. According to our IOVA split history records, Iovance Biotherapeutics has had 0 splits. | |
|
Iovance Biotherapeutics (IOVA) has 0 splits in our IOVA split history database.
Looking at the IOVA split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Iovance Biotherapeutics shares, starting with a $10,000 purchase of IOVA, presented on a split-history-adjusted basis factoring in the complete IOVA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$9.24 |
|
End price/share: |
$14.82 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
60.39% |
|
Average Annual Total Return: |
4.84% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$16,040.35 |
|
Years: |
10.00 |
|
|
|
|
|